Surgery Doctors in Huntington, IN Accepting Medicare

2 Surgery doctors found. Showing 1 - 2

Mr. Boaz Ofek, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 2003 Stults Rd Ste 120, Huntington, IN 46750 Phone: 260-454-0425    Fax: 260-355-0299

Dr. Jeremy R Wilson, D.O. Surgery Medicare: Accepting Medicare Assignments Practice Location: 2003 Stults Rd Ste 120, Huntington, IN 46750 Phone: 260-454-0425    Fax: 260-355-0299

News Archive

Study shows potential of neurofeedback in tinnitus treatment

A study presented today at the annual meeting of the Radiological Society of North America (RSNA) suggests that neurofeedback training has the potential to lessen the severity of tinnitus or even eliminate it.

UHZ cardiologists use innovative catheter technology to repair tricuspid valve

A team led by Francesco Maisano, co-director of the University Heart Center at the University Hospital Zurich and professor for Heart Surgery at the University of Zurich, made up of heart surgeons and cardiologists used new catheter technology to repair a leaky tricuspid valve for the very first time.

Researchers evaluate effects of integrating religious beliefs into depression therapy

For chronically ill patients with major depression, an approach to cognitive-behavioral therapy (CBT) that incorporates patients' religious beliefs is at least as effective as conventional CBT, suggests a study in the April issue of The Journal of Nervous and Mental Disease.

Kaposi's sarcoma-associated herpesvirus senses and reacts to host cell's impending death

A research team led by Children's National Medical Center has identified a trigger that causes latent Kaposi's sarcoma-associated herpesvirus (KSHV) to rapidly replicate itself. KSHV causes Kaposi's sarcoma, primary effusion lymphoma, and other cancers that commonly affect immunocompromised patients, including those with AIDS.

ARIAD's oral ridaforolimus improves PFS in patients with metastatic endometrial cancer

Pharmaceuticals, Inc. today announced interim results of a randomized, open‐label, active-control multicenter Phase 2 study of oral ridaforolimus, an investigational mTOR inhibitor, in patients with metastatic or recurrent endometrial cancer. Based on this interim analysis, the study demonstrated a statistically significant improvement in the primary endpoint of median progression-free survival (PFS) in patients receiving single-agent ridaforolimus compared to patients receiving standard-of-care treatment.

Read more Medical News

› Verified 3 days ago